Good news about the signing

Release time:

2022-12-20

Source:

Author:

Good news about the signing

On December 19, 2022, our company reached a strategic consensus with Japan’s Ribomic Co., Ltd. and Shanghai Huirui Medical Device Co., Ltd. on the clinical development of RBM-007 for age-related macular degeneration (AMD) and other applicable indications. We signed a tripartite framework agreement for a joint venture to jointly advance the clinical development, promotion, and sales of this drug in the Greater China region.

About RBM-007
This drug is targeted at age-related macular degeneration and, by inhibiting the function of fibroblast growth factor 2 (FGF2), exhibits a novel pharmacological mechanism that simultaneously suppresses both angiogenesis and scar formation in age-related macular degeneration. Clinical development of RBM-007 has been conducted in the United States, and three Phase II clinical trials have already been completed. Based on the results of these trials, cases showing symptom improvement were identified in physician-led clinical studies involving untreated patients. Currently, further in-depth development is ongoing, still focusing on untreated patients.

In the future, after the three parties establish a joint venture, they will also explore introducing both Ribomic Co., Ltd. of Japan’s existing and pipeline products into the tripartite joint venture established in China, thereby continuing to provide Chinese consumers with high-quality foreign pharmaceuticals and medical devices.

December 20, 2022

Recommended News

03-06